Floatz logo

Capivasertib

Advanced Non-small-cell Lung Cancer

Shanxi Province Cancer HospitalSmall moleculePhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Advanced Non-small-cell Lung Cancer cohort.

Asset / SponsorPhaseRating
SC 43
RaND Biosciences
Phase 1/2CCC

Same molecule, other indications

Capivasertib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Metastatic Breast CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →